Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 2 von 532

Details

Autor(en) / Beteiligte
Titel
Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility
Ist Teil von
  • Molecular pharmaceutics, 2016-12, Vol.13 (12), p.4141-4151
Ort / Verlag
United States: American Chemical Society
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
  • Disproportionation propensity of salts (HCl, HBr, heminapadisylate) and adipic acid cocrystal of corticotropin releasing hormone receptor-1 antagonist was studied using model free kinetics. Using thermogravimetic weight loss profile or heat flow curves from differential scanning calorimetry, an activation energy plot for salts and cocrystal was generated based on model free kinetics. This activation energy of disproportionation provided qualitative information about the solid state salt stability. To ensure the stability throughout the shelf life, “prototype” formulations of salts and cocrystal in tablet form were stored at 40 °C and several water vapor pressures. Disproportionation kinetics were studied in these prototype tablet formulations using two-dimensional X-ray diffractometry. Formulations containing the adipic acid cocrystal or heminapadisylate salt did not show disproportionation of API when stored at 40 °C/75% RH for 300 days. On the other hand, formulations containing HCl or HBr salt disproportionated. Though isostructural, the disproportionation propensity of HBr and HCl salts was quite different. The HCl salt highlighted the important role that volatility of the counterion plays in the physical stability of the formulations. Solution state stability (i.e., in dissolution medium) of salts and cocrystal was also assessed and compared with solid state stability, by determining their solubility at different pH’s, and intrinsic dissolution rate.
Sprache
Englisch
Identifikatoren
ISSN: 1543-8384
eISSN: 1543-8392
DOI: 10.1021/acs.molpharmaceut.6b00745
Titel-ID: cdi_osti_scitechconnect_1334815

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX